GSW catches Tamiflu consumer work

Share this article:
Roche named GSW Worldwide agency of record for Tamiflu DTC work, following a multi-agency pitch involving FCB, Kaplan-Thaler Group, Digitas and Avenue A|Razorfish.

Under the agreement, the inVentiv agency will take the lead on all consumer advertising and promotion, including strategic planning, media planning and placement, and direct marketing.
The brand has not had a consumer agency of record for several years, though Y&R has performed some consumer work on the account on a project basis. Sudler & Hennessey handles professional advertising and promotion for the antiviral drug, and media planning and buying has been awarded to PHD.

Last month, George Abercrombie, CEO of Roche's Hoffman-LaRoche, said rather than relying on governments, companies should stockpile enough vaccines and drugs to protect at least a quarter of their workers from the avian flu. “Stockpiling is necessary,” said Abercrombie. “We can't flip a switch to produce massive amounts of Tamiflu during a pandemic.”

Tamiflu was co-developed by Roche and Gilead Sciences and is indicated for the treatment of uncomplicated influenza caused by virus types A and B, but has seen a boom of interest since emerging as a potential treatment for avian flu. In May, World Health Organization asked Roche to be ready to ship its stockpile of Tamiflu to Indonesia amid an avian flu outbreak there, and the WHO deployed its own 9,500-dose stockpile of the drug from to blunt the crisis.

Share this article:
close

Next Article in News

Email Newsletters

More in News

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.

GSK, Novartis, Lilly play musical chairs

GSK, Novartis, Lilly play musical chairs

The three drugmakers rearranged part of the pharma universe Tuesday with a string of pipeline-altering deals.

Valeant bids $47B for Allergan

Valeant bids $47B for Allergan

The deal would bring Allergan's Botox and Juvederm under the same roof as Restylane.